| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 34.52 | 2.3% | 34.4% |
| Total Income | 34.52 | 2.3% | 34.4% |
| Expenditure | 23.23 | 24.4% | 45.2% |
| PBT | — | ||
| Net Profit | -0.60 | 101.5% | 97.9% |
| OPM | 32.72% | 11.91pp | 97.76pp |
| NPM | -1.75% | 101.75pp | |
| EPS | -0.01 | 101.0% | 99.0% |
Agenus Reports Q2 2026 Results and Advances Phase 3 ROBBIN Trial
06 Aug 2026 · 6 Aug, 5:31 pm
Summary
Agenus reported second quarter 2026 total revenue of $34.5 million, an increase from $25.7 million in the prior year, driven by $6.4 million in pre-commercial product revenue from access programs. The company also announced the completion of an $85 million private placement to fund its Phase 3 ROBBIN trial for BOT+BAL in neoadjuvant MSS colon cancer, a significant market opportunity estimated at over $7 billion annually in the U.S. Management highlighted that the financing provides a clear path to act on clinical evidence and pursue the opportunity with focus and urgency, with ROBBIN initiation expected in Q1 2027.
Key Highlights
- 1
Agenus reported $6.4 million in second-quarter pre-commercial product revenue from authorized access programs, an increase from $4.6 million in the first quarter of 2026.
- 2
Total revenue for the second quarter of 2026 was $34.5 million, compared to $25.7 million a year earlier.
- 3
Total revenue for the first six months of 2026 was $68.3 million, compared to $49.8 million a year earlier.
- 4
The company announced an oversubscribed $85 million private placement in July 2026, with potential for up to $255 million in milestone-aligned warrants, to support the Phase 3 ROBBIN trial.
- 5
The ROBBIN trial, evaluating BOT+BAL in neoadjuvant MSS colon cancer, is expected to initiate with first patient dosing in the first quarter of 2027.
- 6
ROBBIN addresses an estimated 38,000 newly diagnosed patients annually in the United States and represents an estimated annual addressable sales opportunity of more than $7 billion.
- 7
Manuscripts with longer-term follow-up from the NEST and UNICORN studies are anticipated in the second half of 2026.
Management Comments
Garo H. Armen
The financing completed in July gives us a clear path to act on the clinical evidence supporting BOT+BAL in a large, underserved patient population. The previously reported neoadjuvant findings support testing whether BOT+BAL before surgery can reduce recurrence and improve the potential for cure. With capital aligned to ROBBIN’s development milestones, we are positioned to pursue that opportunity with focus and urgency.
Informational and educational content only. Not investment advice.